About OJO | Search | Ahead of print | Current Issue | Archives | Author Instructions | Reviewer Guidelines | Online submissionLogin 
Oman Journal of Ophthalmology Oman Journal of Ophthalmology
  Editorial Board | Subscribe | Advertise | Contact
https://www.omanophthalmicsociety.org/ Users Online: 269  Wide layoutNarrow layoutFull screen layout Home Print this page  Email this page Small font size Default font size Increase font size

Year : 2010  |  Volume : 3  |  Issue : 1  |  Page : 26-28 Table of Contents   

Topiramate-induced angle closure with acute myopia, macular striae

Departments of Vitreoretina, Glaucoma and Cataract and Refractive Surgery Narayana Nethralaya, Bangalore, India

Date of Web Publication18-Feb-2010

Correspondence Address:
S Natesh
34, Model Housing colony, Basaveswaranagar, Bangalore
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-620X.60018

Rights and Permissions

Topiramate is a sulfamate-substituted monosaccharide used in the treatment of seizures, and prophylaxis of migraine. A number of ocular side-effects have been described with use of topiramate, like bilateral angle closure, acute myopia and macular striae. Ultrasound biomicroscopy (UBM) clinches the diagnosis after ruling out other causes of shallow anterior chamber. Previous studies have not demonstrated internal limiting membrane folds presenting as macular striae. We report a case of topiramate-induced acute myopia with angle closure and macular striae in a young adult. This is the first report wherein striae formation after low doses of topiramate and their resolution have been documented by Optical Coherence Tomography (OCT).

Keywords: Topiramate, macular striae, optical coherence tomography

How to cite this article:
Natesh S, Rajashekhara S K, Rao A, Shetty B. Topiramate-induced angle closure with acute myopia, macular striae. Oman J Ophthalmol 2010;3:26-8

How to cite this URL:
Natesh S, Rajashekhara S K, Rao A, Shetty B. Topiramate-induced angle closure with acute myopia, macular striae. Oman J Ophthalmol [serial online] 2010 [cited 2023 Feb 2];3:26-8. Available from: https://www.ojoonline.org/text.asp?2010/3/1/26/60018

   Introduction Top

Topiramate is a sulfamate-substituted drug used primarily for the treatment of seizures and as prophylaxis for migraine headaches. The doses used commonly are in the range of 50 mg - 400 mg per day. A number of ocular side-effects have been described with use of topiramate, namely bilateral angle closure, acute myopia and macular striae. [1],[2]

Drug-induced myopia has been described with the use of topiramate, acetazolamide, spiranolactone, corticosteroids, sulfamethoxazole/trimethoprim, indapamide, promethazine, spironolactone, isosorbide-dinitrate and bromocriptine, tetracycline, hydro-chlorothiazide, penicillamine, quinine, metronidazole, isotretinoin, and aspirin. [3],[4] The basic mechanism underlying drug-induced acute myopia with topiramate seems to be ciliary effusion causing ante-version of the ciliary body and anterior displacement of the iris-lens diaphragm. This induces bilateral acute myopia, non pupillary block angle closure, and raised intraocular pressure (IOP). [5]

We report a case wherein low doses of topiramate caused angle closure with acute myopia, documented with ultrasound biomicroscopy (UBM). The drug also caused development of macular striae, which was noted clinically and documented with optical coherence tomography (OCT). This is the first OCT documented report of macular striae with use of topiramate and its resolution.

   Case Report Top

A 23-year-old male presented with blurred vision in both eyes (OU) of two days duration. This was accompanied by mild redness and discomfort OU. There was a previous documentation of his refractive error, which was less than one diopter of myopia OU. He was on oral topiramate, 25 mg once daily for vascular migraine since five days.

On examination, his vision showed improvement to 20/20 OU with myopic correction of 26 diopters OU. Anterior segment showed bilateral shallow angles and gonioscopy showed occludable angles opening up to Schwalbe's line. There was no pupillary abnormality. His intraocular pressure (IOP) was 24 mm of Hg OU. Fundus evaluation showed attached retina, healthy optic discs and macular striae.

Color vision was normal and optical coherence tomography (OCT) (spectralis HRA-OCT, Heidelberg engineering) showed striae at the level of the internal limiting membrane [Figure 1]a. No subfoveal fluid was noted. Ultra sound biomicroscopy (35 Hz, OTI, Canada) showed angle closure, anteversion of the ciliary body with ciliary effusion [Figure 2]. B scan ultrasonography showed diffuse choroidal effusion. The patient was asked to discontinue topiramate and was treated with topical cycloplegics and corticosteroid drops. IOP was 14 mm Hg OU next day and anterior chamber was better formed. In two days his vision recovered to 20/20. Macular striae resolved [Figure 1]b and gonioscopy showed open angles up to the scleral spur.

   Discussion Top

Angle closure and acute myopia occurs due to ciliary effusion, as an idiosyncratic reaction to topiramate. [3] Weak carbonic anhydrase activity of the topiramate and prostaglandin mediated effect is implicated to be the cause of ciliochoroidal effusion. [5],[6] Prompt resolution following early discontinuation of the drug is the norm although some patients need IOP lowering medications. Peripheral iridectomy is of doubtful value. Ciliary effusion seen well on the UBM, clinches the diagnosis, ruling out other causes of shallow anterior chamber such as accommodative spasm, and primary angle closure.

Topiramate is commonly used in the range of 50 - 100 mg per day although some neurologists prefer to treat with the doses as high as 400 mg per day Even after an episode of angle closure, topiramate can be continued at a low dose of 12.5 mg per day and is reported to be less associated with recurrence. However, there have been reports of angle closure glaucoma with plasma topiramate levels less than therapeutic levels. [5] Our patient was on only 25 mg per day of the drug, which suggests that the reaction is not a dose dependent toxicity.

Macular striae were demonstrated on the OCT in our case. Fine folds at the level of the internal limiting membrane (ILM) were seen with resolution and restoration of normal visual acuity along with resolution of myopia and angle closure after discontinuation of topiramate [Figure 1]b. Although macular striae have been reported previously they have not been demonstrated by OCT [7],[8] and were thought to be due to the vitreomacular traction. [7] Topiramate has effects on sodium and chloride movement that can interfere with ionic concentration in various tissues, including the crystalline lens. Elevation of the retina is secondary to fluid consistent with drug-induced altered membrane potential. [9] We hypothesize that the macular striae due to ILM folds may be due to the volume effect of the choroidal effusion. Spectral domain OCT with a better axial resolution (4.5 microns) is ideal for recording the fine striae. OCT due to its limited penetration into the choroid could not image the choroidal effusion. B scan, however, showed diffuse thickening of the choroid.

This case report illustrates angle closure, acute myopia, and retinal striae occurring even with low doses of topiramate. UBM evaluation of such a presentation is of immense value in ruling in this diagnosis.

   References Top

1.Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology 2004;111:1275-9.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]  
2.Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46:1684-90.  Back to cited text no. 2      
3.Akbarian MA, Mehrpour M. A Case report on toriramate induced myopia. Ir j pharma and therap 2004;3:66-7.  Back to cited text no. 3      
4.Panday VA, Rhee DJ. Review of sulfonamide-induced acute myopia and acute bilateral angle-closure glaucoma. Compr Ophthalmol Update 2007;8:271-6.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.Spaccapelo L, Leschiutta S, Aurea C, Ferrari A. Topiramate-associated acute glaucoma in a migraine patient receiving concomitant citalopram therapy: A case-report. Cases J 2009;2:87.  Back to cited text no. 5      
6.Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 2004;111:109-11.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]  
7.LIN RC,Cantrill HL, Mieler WF. Retinal toxicities caused by systemic medications. Retinal physicians. http://www.retinalphysician.com/article.aspx.article=101094   Back to cited text no. 7      
8.Beyenburg S, Weyland C, Reuber M. Presumed topiramate induced maculopathy, Epilepsy and Behavior; 2009. p. 556-9.  Back to cited text no. 8      
9.Sen HA, O′Halloran HS, Lee WB, Ky L, Topiramate-induced acute myopia and retinal striae Arch Ophthalmol 2001;119:775-7.  Back to cited text no. 9      


  [Figure 1], [Figure 2]

This article has been cited by
1 The Ophthalmic Side Effects of Topiramate: A Review
Monia Mechrgui, Suleman Kanani
Cureus. 2022;
[Pubmed] | [DOI]
2 Psychopharmacological Treatment, Intraocular Pressure and the Risk of Glaucoma: A Review of Literature
Adela Magdalena Ciobanu, Vlad Dionisie, Cristina Neagu, Otilia Maria Bolog, Sorin Riga, Ovidiu Popa-Velea
Journal of Clinical Medicine. 2021; 10(13): 2947
[Pubmed] | [DOI]
3 Acute bilateral myopia induced by Triplixam: a case report
Ruta Jaruseviciene, Ginte Sirvydyte
BMC Ophthalmology. 2020; 20(1)
[Pubmed] | [DOI]
4 Glaucoma agudo de ángulo cerrado inducido por topiramato con miopización aguda y estrías maculares: a propósito de un caso
M.A. Sierra-Rodríguez, L. Rodríguez-Vicente, J.J. Chavarri-García, J.L. del Río-Mayor
Archivos de la Sociedad Española de Oftalmología. 2019; 94(3): 130
[Pubmed] | [DOI]
5 Simultaneous Bilateral Acute Angle-Closure Glaucoma in Miller Fisher Syndrome
Jana Štepánková, Lenka Kinštová, Ivana Gažová, Martina Kodetová, Jirí Cendelín, Nina Ondrová, Dagmar Otrelová
Czech and Slovak Ophthalmology. 2019; 75(4): 210
[Pubmed] | [DOI]
6 Topiramate maculopathy
William Gualtieri,Jan Janula
International Ophthalmology. 2013; 33(1): 103
[Pubmed] | [DOI]
7 Topiramate-induced acute myopia with MRI contrast enhancement
Manuel Facundo Latini,Lucas Martín Romano
Acta Neurologica Belgica. 2012; 112(1): 81
[Pubmed] | [DOI]
8 Drug-induced Angle-Closure Glaucoma
Bhawna Khurana, Aruj K Khurana, Ashok K Khurana
Journal of Current Glaucoma Practice. 2012; 6(1): 6
[Pubmed] | [DOI]
9 Clinical pharmacology of topiramate in migraine prevention
Anna Ferrari,Ilaria Tiraferri,Laura Neri,Emilio Sternieri
Expert Opinion on Drug Metabolism & Toxicology. 2011; 7(9): 1169
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Case Report
    Article Figures

 Article Access Statistics
    PDF Downloaded698    
    Comments [Add]    
    Cited by others 9    

Recommend this journal